search
Back to results

WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP) (PrEP)

Primary Purpose

HIV-infection/AIDS

Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cultural adaptation of a patient-provider communication tool
Sponsored by
University of Alabama at Birmingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for HIV-infection/AIDS focused on measuring Pre exposure prophylaxis (PrEP), HIV prevention, African American women

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion/Exclusion Criteria

Patients

  • Cisgender
  • African American
  • HIV-uninfected women
  • Age 18 years or older
  • English speaking
  • Report HIV risk and/or recent PrEP use.

Providers

  • Physicians, nurse practitioners, physician assistants, nurses, medical assistants, social workers/counselors or other potential/actual PrEP service providers
  • English speaking

Sites / Locations

  • University of Alabama at Birmingham

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Cultural adaptation of a patient-provider communication tool

Arm Description

Strengthening of the PrEP care continuum by developing and testing an intervention designed to improve PrEP awareness, screening, engagement, retention, adherence, and persistence among individuals at substantial risk for HIV infection; developing and testing an intervention to reduce racial/disparities in PrEP uptake and use.

Outcomes

Primary Outcome Measures

PrEP uptake changes
To examine changes in PrEP uptake rates in the participating clinics comparing 3 years before and the year after the implementation of the protocol. Uptake will be calculated by the ratio of patients initiating PrEP to the number of eligible patients screened.
Intervention feasibility changes
The following variable will be analyzed to determine feasibility: Number of participants screened, enrolled, and number who agreed to use PrEP and adhered to their prescribed regimen; reasons for declining enrollment, prematurely leaving the study, refusing a referral, failing to attend a PrEP clinic visit, and/or discontinuing PrEP. Recruitment and scheduling strategies, participant contact, and feasibility of administering instruments (e.g. assessment duration), will be documented and analyzed at each time frame.
Intervention acceptability
All participants will be asked to consent to an in-depth, qualitative phone interview exploring their perceptions of the study, as well as an evaluation of the PrEP uptake intervention.

Secondary Outcome Measures

PrEP adherence
The AIDS Clinical Trials Group (ACTG) Adherence Questionnaire (i.e. Visual Analog Scale only) will be used to assess PrEP adherence, as is currently practice in the participating clinics. ACTG 's scores range from 0-4 with 4 indicating more adherence with 0 least adherent.
Clinic visit adherence changes
The following variable will be analyzed to determine adherence: PrEP visits adhered to, divided by visits scheduled. The change in retention to clinic care visits will be assessed at each assessment over 6-month intervals, which is in line with the 6 months post-intervention interval.
Biological measures of HIV, STIs and pregnancy
HIV and pregnancy tests (every visit) and STI tests (baseline and 6 months) will be performed for all patients. This combined data will help to identify biological measures.

Full Information

First Posted
April 28, 2020
Last Updated
April 26, 2023
Sponsor
University of Alabama at Birmingham
Collaborators
National Institute of Mental Health (NIMH), Massachusetts General Hospital, Beth Israel Deaconess Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04373551
Brief Title
WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)
Acronym
PrEP
Official Title
PrEP Demonstration Project Among Women at Risk for HIV Infection
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
April 14, 2020 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alabama at Birmingham
Collaborators
National Institute of Mental Health (NIMH), Massachusetts General Hospital, Beth Israel Deaconess Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of this application is to increase PrEP uptake among AA women at-risk for HIV-infection in the rural South, specifically those seeking care at Federally Qualified Healthcare Centers (FQHC) in rural Alabama. The investigators will use a mixed-methods approach to adapt and pilot test a patient-provider communication tool from the CDC PrEP toolkit that focuses on the first three steps of the PrEP cascade (e.g., recognizing HIV risk, identifying as a PrEP candidate, and interested in PrEP) to increase PrEP uptake via referrals to local PrEP clinics.
Detailed Description
The investigators propose: (1) to explore the HIV risk perceptions of AA women with recent PrEP use, AA women who are candidates for PrEP, and providers and identify preferences around patient-provider communication about HIV risk and PrEP services that address the needs of AA women. (2A) To systematically adapt a patient-provider communication tool to increase PrEP uptake at two FQHCs in rural Alabama, using an iterative implementation process; and (2B). To assess the feasibility, acceptability, and preliminary impact of the patient-provider communication intervention on PrEP uptake among AA women and their providers in a pilot pre-/post-intervention design. As part of aim 2B), the investigators will also systematically document and evaluate reasons for declining a PrEP referral, reasons for incomplete referrals, reasons for failing to initiate PrEP after a successful referral, and ongoing PrEP use at 3 months and 12 months post PrEP initiation among our sample.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV-infection/AIDS
Keywords
Pre exposure prophylaxis (PrEP), HIV prevention, African American women

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
125 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cultural adaptation of a patient-provider communication tool
Arm Type
Experimental
Arm Description
Strengthening of the PrEP care continuum by developing and testing an intervention designed to improve PrEP awareness, screening, engagement, retention, adherence, and persistence among individuals at substantial risk for HIV infection; developing and testing an intervention to reduce racial/disparities in PrEP uptake and use.
Intervention Type
Behavioral
Intervention Name(s)
Cultural adaptation of a patient-provider communication tool
Other Intervention Name(s)
CDC PrEP tool kit
Intervention Description
Adaptation of a patient-provider communication tool for PrEP uptake utilized among AA women and their providers in a pilot pre/post-intervention design.
Primary Outcome Measure Information:
Title
PrEP uptake changes
Description
To examine changes in PrEP uptake rates in the participating clinics comparing 3 years before and the year after the implementation of the protocol. Uptake will be calculated by the ratio of patients initiating PrEP to the number of eligible patients screened.
Time Frame
baseline, 3 months, and 12 months
Title
Intervention feasibility changes
Description
The following variable will be analyzed to determine feasibility: Number of participants screened, enrolled, and number who agreed to use PrEP and adhered to their prescribed regimen; reasons for declining enrollment, prematurely leaving the study, refusing a referral, failing to attend a PrEP clinic visit, and/or discontinuing PrEP. Recruitment and scheduling strategies, participant contact, and feasibility of administering instruments (e.g. assessment duration), will be documented and analyzed at each time frame.
Time Frame
baseline, 3 months, and 12 months
Title
Intervention acceptability
Description
All participants will be asked to consent to an in-depth, qualitative phone interview exploring their perceptions of the study, as well as an evaluation of the PrEP uptake intervention.
Time Frame
Through study completion, an average of 12 months
Secondary Outcome Measure Information:
Title
PrEP adherence
Description
The AIDS Clinical Trials Group (ACTG) Adherence Questionnaire (i.e. Visual Analog Scale only) will be used to assess PrEP adherence, as is currently practice in the participating clinics. ACTG 's scores range from 0-4 with 4 indicating more adherence with 0 least adherent.
Time Frame
3 months and 12 months
Title
Clinic visit adherence changes
Description
The following variable will be analyzed to determine adherence: PrEP visits adhered to, divided by visits scheduled. The change in retention to clinic care visits will be assessed at each assessment over 6-month intervals, which is in line with the 6 months post-intervention interval.
Time Frame
3 months and 12 months
Title
Biological measures of HIV, STIs and pregnancy
Description
HIV and pregnancy tests (every visit) and STI tests (baseline and 6 months) will be performed for all patients. This combined data will help to identify biological measures.
Time Frame
baseline, 3 months, and 12 months

10. Eligibility

Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion/Exclusion Criteria Patients Cisgender African American HIV-uninfected women Age 18 years or older English speaking Report HIV risk and/or recent PrEP use. Providers Physicians, nurse practitioners, physician assistants, nurses, medical assistants, social workers/counselors or other potential/actual PrEP service providers English speaking
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mirjam-Colette Kempf, PhD, MPH
Organizational Affiliation
University of Alabama at Birmingham
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Our data sharing plans will be discussed with our NIH program officer and based on their feedback, may be altered. Our current plans call for the results of the process and outcome evaluations collected as part of this project will be shared via professional presentations and publications, and will also be shared upon request. De-identified data will also be electronically encrypted and archived for use by others who are interested in using this data. New procedures, protocols, data collection instruments and analytic routines will be made available to interested investigators.
IPD Sharing Time Frame
Data will be available after analysis is completed.
IPD Sharing Access Criteria
Only de-identified information will be available.

Learn more about this trial

WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)

We'll reach out to this number within 24 hrs